Testosterone blood pressure labeling: FDA dates and product records

The February 2025 action made two different changes

In its February 28, 2025 announcement, FDA described removing boxed-warning language about increased adverse cardiovascular outcomes after reviewing TRAVERSE. It also required blood-pressure warning changes based on ambulatory blood-pressure studies. Reading only the warning-removal part leaves out a material part of the same action.

FDA said the completed blood-pressure studies confirmed increases across the testosterone product class. That is a reason for product-specific counseling and monitoring, not a statement that every person will experience the same increase. It also does not establish that every product had identical boxed wording before the change. The relevant question is what the actual medicine’s current information requires.

The FDA discussion here retains the account checked on September 27, 2026. The November 8, 2026 research check did not retrieve fresh FDA text. That access limit neither reverses the earlier account nor establishes today’s wording; it means this revision cannot claim a newly verified agency position.

TRAVERSE tested a defined treatment in a defined group

The primary TRAVERSE report describes a randomized, placebo-controlled trial in men aged 45 to 80 with hypogonadism and preexisting cardiovascular disease or high cardiovascular risk. The treatment was transdermal testosterone gel, not testosterone cypionate injections. Participants had symptoms and repeated low fasting testosterone measurements under the study’s entry criteria.

Those details are part of the finding, not fine print that can be discarded. The trial can inform an important safety question while leaving other populations, formulations and routes less directly studied. It does not test an online service’s compounded preparation, its dispensing process or an individual injection plan. An advertisement citing the trial should preserve that boundary.

The original trial report was not retrieved in the November 8 check. The trial description above remains the historical account, not a new analysis. When reading a later summary, keep a separate note for the study it cites and for the conclusion the summary’s author draws; those are two records to examine.

Noninferiority does not mean that every possible harm was absent

TRAVERSE’s main cardiovascular endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke. The published abstract reports that testosterone gel was noninferior to placebo for that endpoint under the trial design. It also reports higher observed incidences of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group.

These observations should not be flattened into either complete cardiovascular danger or universal safety. The study was designed around a particular main question and had a limited follow-up period. The Endocrine Society’s July 2026 statement continues to emphasize unresolved long-term safety questions and the need for screening and monitoring. A reassuring main result does not erase other clinical considerations.

The July 16, 2026 Endocrine Society statement is professional commentary. It is distinct from the March 19, 2018 guideline resource and is not a new clinical practice guideline or the original trial report.

Blood pressure remains a separate follow-up responsibility

The Depo-Testosterone prescribing information checked for this guide states that testosterone can raise blood pressure and calls for periodic monitoring. It also contains cautions relevant to people with uncontrolled hypertension. This is an exact cypionate product record, not an individualized instruction or a complete safety profile for every preparation sold under the word testosterone.

Ask how blood pressure will be assessed, who receives readings and who is responsible for responding to a concerning change. Other clinicians managing cardiovascular conditions should know about the proposed treatment. This article does not supply a blood-pressure cutoff or tell you to alter either testosterone or a blood-pressure medicine. The monitoring arrangements need to come from the clinicians responsible for care.

The care team should also explain how follow-up continues when a prescription is renewed or a pharmacy changes. A renewed prescription does not establish that the relevant cardiovascular history, current medicines or recent measurements have been reviewed. Keep the responsibility for that review explicit.

A blank handoff note could ask: which clinician should receive the information, how will receipt be acknowledged, and where will the explanation appear? Leave the answer open until that person or team confirms it. Writing a name in your own notes is a proposed contact, not evidence that responsibility has been accepted.

The June 2026 request changed another part of the story

Our September 27, 2026 account of the FDA information page described a June 2026 request about age-related limitations and prostate safety wording. That dated account remains relevant to the chronology; this revision does not present it as freshly retrieved FDA text.

The Pfizer file and DailyMed text have different printed revisions. Their excipient quantities also differ. A record-update date does not settle which document matches a patient’s preparation; ask the pharmacist to reconcile the actual product record.

For your own document folder, keep the file name, the page carrying the revision and the date you obtained it together. If two copies disagree, preserve both and write down the unanswered question instead of replacing one silently. The table separates document fields; it is not a decision about which medicine to use.

Keep the injection’s identity separate from the class evidence

CoreAge’s page names testosterone cypionate and describes compounding. That does not establish the complete formulation or individual dispensing pharmacy, and it cannot supply another product’s approved route or clinical evidence. An exact medicine record and a provider’s general description therefore need to remain separate.

FDA explains that compounded medicines are not FDA-approved. Neither the existence of an approved cypionate label nor the class-wide safety discussion confers approval on an unidentified compounded product. Our CoreAge review examines the public record without making that transfer of evidence.

Try a three-part document question: what does the service say it offers, what does the pharmacy identify as the supplied product, and what did the prescriber explain about that product? Record an unanswered part as unanswered. A familiar name in the first document should not fill a blank in the other two.

Use the update to ask better questions about ongoing care

A useful consultation should connect diagnosis, expected benefit, cardiovascular history and monitoring rather than use a regulatory headline to close the conversation. Our testing guide explains diagnostic confirmation, and the follow-up record guide connects test results with responsibility for reviewing them. The latest label is one part of that assessment, not a substitute for it.

Our care comparison addresses service arrangements. This is no clinical endorsement. TRAVERSE did not test that service, and the provider records are discussed without ratings or preferred placement. The practical outcome should be a clear explanation of the actual medicine, relevant uncertainties and how benefit and adverse effects will be reviewed over time.

At the next conversation, it may help to bring one focused question about the apparent discrepancy rather than a stack of competing conclusions. For example: “These documents carry different dates. Which one are you using for my record, and where can I find your explanation?” That is a request for clarification, not a request to change treatment.

A care-service record and a product document have different jobs

The Mount Sinai review and UC Davis Health review examine documented assessment roles while leaving the selected medicine unresolved. Their service descriptions cannot replace the exact product information discussed in this guide. A dated regulatory request, an available prescribing document and a clinician’s explanation should remain identifiable as different records. None alone establishes what an individual has received or resolves every question about follow-up.

The Geisinger review uses a named endocrinologist’s hypogonadism practice to establish clinical relevance. A clinician profile supplies a different kind of information from a dated prescribing document.

An original document-folder example has three tabs: service description, product information and visit explanation. Under each tab, note what it answers and what it leaves open. The service tab might explain why you began reading; it cannot stand in for the visit note. Keep the unresolved question visible when moving between them.